瑞尔玛达治疗公司报告了2025年第四季度的亏损,但对其在膀癌中使用NDV-01药物的有希望的II期结果进行分享,导致FDA批准的III期试验将于2026年中开始. Relmada Therapeutics reported a Q4 2025 loss but shared promising phase II results for its NDV-01 drug in bladder cancer, leading to FDA-approved phase III trials set to begin mid-2026.

雷尔马达治疗公司报告了2025年第四季度每股0.29美元的亏损,由于费用上而缺失估计值,但对其NDV-01药物在高风险非肌肉侵入性膀癌中共享积极的II期数据,显示12个月后76%的完整反应率,包括80%的BCG不响应患者,没有疾病进展或严重副作用. Relmada Therapeutics reported a Q4 2025 loss of $0.29 per share, missing estimates, due to rising expenses, but shared positive phase II data for its NDV-01 drug in high-risk non-muscle-invasive bladder cancer, showing a 76% complete response rate at 12 months, including 80% in BCG-unresponsive patients, with no disease progression or severe side effects. 该公司获得了FDA对两条途径的第三期RESCUE计划的同意,该项目将于2026年中启动,预计到今年年底初步结果. The company secured FDA agreement on a two-pathway phase III RESCUE program, set to launch mid-2026, with initial results expected by year-end. 它筹集了1.6亿美元,在2025年结束时拥有9300万美元的现金,并通过2029年的运营融资. It raised $160 million, ending 2025 with $93 million in cash, funding operations through 2029. 它的主要候选者REL-1017正在向2026年中期的普拉德-威利综合征概念验证试验迈进. Its lead candidate, REL-1017, is advancing toward a mid-2026 proof-of-concept trial in Prader-Willi syndrome.